IL-5 Inhibitor Treatment in Drug Reaction With Eosinophilia and Systemic Symptoms

Baraa Hijaz^{1

2}, Vinod E Nambudiri^{1

2}, Sotonye Imadojemu^{1

2}

Affiliations

Baraa Hijaz et al. JAMA Dermatol. 2025.

. 2025 Jun 1;161(6):661-663.

doi: 10.1001/jamadermatol.2025.0441.

Baraa Hijaz^{1

2}, Vinod E Nambudiri^{1

2}, Sotonye Imadojemu^{1

2}

¹ Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.

No abstract available

Plain language summary

This case series evaluates the safety and efficacy of IL-5 inhibition for the treatment of drug reaction with eosinophilia and systemic symptoms.

Conflict of Interest Disclosures: Dr Nambudiri reported royalties from McGraw-Hill outside the submitted work. No other disclosures were reported.

1. Calle AM, Aguirre N, Ardila JC, Cardona Villa R. DRESS syndrome: a literature review and treatment algorithm. World Allergy Organ J. 2023;16(3):100673. doi: 10.1016/j.waojou.2022.100673 - DOI - PMC - PubMed
1. De A, Rajagopalan M, Sarda A, Das S, Biswas P. Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature. Indian J Dermatol. 2018;63(1):30-40. doi: 10.4103/ijd.IJD_582_17 - DOI - PMC - PubMed
1. Maverakis E, Ji-Xu A, Brüggen MC. Targeting interleukin-5 with benralizumab: a novel treatment for drug rash with eosinophilia and systemic symptoms. Allergy. 2022;77(8):2287-2289. doi: 10.1111/all.15283 - DOI - PubMed
1. Gschwend A, Helbling A, Feldmeyer L, et al. Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS). Allergo J Int. Published online August 23, 2022. doi: 10.1007/s40629-022-00224-7 - DOI - PMC - PubMed
1. Schmid-Grendelmeier P, Steiger P, Naegeli MC, et al. Benralizumab for severe DRESS in two COVID-19 patients. J Allergy Clin Immunol Pract. 2021;9(1):481-483.e2. doi: 10.1016/j.jaip.2020.09.039 - DOI - PMC - PubMed